PE20230388A1 - CRYSTALLINE RET INHIBITOR - Google Patents

CRYSTALLINE RET INHIBITOR

Info

Publication number
PE20230388A1
PE20230388A1 PE2022002417A PE2022002417A PE20230388A1 PE 20230388 A1 PE20230388 A1 PE 20230388A1 PE 2022002417 A PE2022002417 A PE 2022002417A PE 2022002417 A PE2022002417 A PE 2022002417A PE 20230388 A1 PE20230388 A1 PE 20230388A1
Authority
PE
Peru
Prior art keywords
crystalline
ret inhibitor
ppm
peaks
selpercatinib
Prior art date
Application number
PE2022002417A
Other languages
Spanish (es)
Inventor
Rajni Miglani Bhardwaj
Mark Steven Kerr
Douglas Patton Kjell
Jeremy Miles Merritt
Jon Gordon Selbo
Shekhar Krishna Viswanath
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of PE20230388A1 publication Critical patent/PE20230388A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Una forma cristalina de selpercatinib, que se caracteriza por al menos uno de: (a) un patron de difraccion de rayos X en polvo (XRPD) que comprende un pico a 21,1 y uno o mas picos a 17,1 , 17,7 y 19,8 0,2 2? medidos utilizando una longitud de onda de rayos X de 1,5418 ; o (b) un espectro de NMR de 13C en estado solido que comprende picos referidos a la resonancia de campo alto de adamantano (? = 29,5 ppm) a: 28,0, 48,0, 80,4, 106,8, 130,2 y 134,9ppm ( 0,2 ppm, respectivamente).A crystalline form of selpercatinib, characterized by at least one of: (a) an X-ray powder diffraction (XRPD) pattern comprising a peak at 21.1 and one or more peaks at 17.1, 17, 7 and 19.8 0.2 2? measured using an X-ray wavelength of 1.5418; or (b) a solid state 13C NMR spectrum comprising peaks referred to the high field resonance of adamantane (? = 29.5 ppm) at: 28.0, 48.0, 80.4, 106.8 , 130.2 and 134.9ppm (0.2 ppm, respectively).

PE2022002417A 2020-04-17 2021-04-09 CRYSTALLINE RET INHIBITOR PE20230388A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063011701P 2020-04-17 2020-04-17
US202163151354P 2021-02-19 2021-02-19
PCT/US2021/026611 WO2021211380A1 (en) 2020-04-17 2021-04-09 Crystalline ret inhibitor

Publications (1)

Publication Number Publication Date
PE20230388A1 true PE20230388A1 (en) 2023-03-06

Family

ID=75747118

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002417A PE20230388A1 (en) 2020-04-17 2021-04-09 CRYSTALLINE RET INHIBITOR

Country Status (17)

Country Link
EP (1) EP4136090A1 (en)
JP (1) JP2023522012A (en)
KR (1) KR20230002706A (en)
CN (1) CN115916791A (en)
AU (1) AU2021255488A1 (en)
BR (1) BR112022020446A2 (en)
CA (1) CA3174316A1 (en)
CL (1) CL2022002849A1 (en)
CO (1) CO2022014882A2 (en)
CR (1) CR20220520A (en)
DO (1) DOP2022000221A (en)
EC (1) ECSP22080982A (en)
IL (1) IL297212A (en)
MX (1) MX2022012952A (en)
PE (1) PE20230388A1 (en)
TW (1) TW202202501A (en)
WO (1) WO2021211380A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022069357A1 (en) * 2020-10-01 2022-04-07 Sandoz Ag Crystalline form of selpercatinib
WO2023114119A1 (en) 2021-12-13 2023-06-22 Loxo Oncology, Inc. Processes for the preparation of the crystalline form a of selpercatinib. a ret inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI704148B (en) * 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI812649B (en) * 2017-10-10 2023-08-21 美商絡速藥業公司 Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
TWI791053B (en) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof
TWI783057B (en) 2017-10-10 2022-11-11 美商絡速藥業公司 Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
EP3845531A4 (en) * 2018-09-30 2021-11-24 Applied Pharmaceutical Science, Inc. Substituted pyrazole fused ring derivative, preparation method therefor, and application thereof
CN111004257B (en) * 2019-12-24 2021-06-29 武汉九州钰民医药科技有限公司 Method for preparing RET inhibitor Selpercatinib

Also Published As

Publication number Publication date
TW202202501A (en) 2022-01-16
BR112022020446A2 (en) 2022-11-29
JP2023522012A (en) 2023-05-26
CN115916791A (en) 2023-04-04
DOP2022000221A (en) 2023-01-15
CA3174316A1 (en) 2021-10-21
CR20220520A (en) 2022-11-15
CO2022014882A2 (en) 2022-10-31
IL297212A (en) 2022-12-01
KR20230002706A (en) 2023-01-05
MX2022012952A (en) 2023-01-11
ECSP22080982A (en) 2023-01-31
WO2021211380A1 (en) 2021-10-21
CL2022002849A1 (en) 2023-06-16
AU2021255488A1 (en) 2022-11-10
EP4136090A1 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
PE20230388A1 (en) CRYSTALLINE RET INHIBITOR
Macrander et al. X-ray optics testing beamline 1-BM at the advanced photon source
CN112925176A (en) Radiation source
WO2008155894A1 (en) Optical waveform shaping device
ECSP055567A (en) INDOLINONA DERIVATIVES SUBSTITUTED IN POSITION 6, ITS PREPARATION AND ITS USE AS MEDICATIONS
CN103149809B (en) Off-axis illuminating device for photoetching machine equipment
Brown Synchrotron Emission on the Largest Scales: Radio Detection of the Cosmic-Web
JP6909873B2 (en) Alignment measurement system
Takano Beam diagnostics with synchrotron radiation in light sources
WO2006040347A1 (en) Calibration of optical line shortening measurements
WO2015019187A3 (en) System and method for return beam metrology with optical switch
WO2014128010A8 (en) Euv light source for generating a used output beam for a projection exposure apparatus
TW200630604A (en) Method and apparatus for inspection of optical component
CN113126205B (en) Sectional type plane imaging system and method based on optical switch
AR121800A1 (en) CRYSTALLINE RET INHIBITOR
CL2022001087A1 (en) 3-(Difluoromethyl)-1-methyl-n-(1,1,3-trimethyl-2,3-dihydro-1h-inden-4-yl)-1h-pyrazole-4-carboxamide crystal
AR103209A1 (en) 4-METHYLBENCIL (3S, 4R) -3-FLUORO-4 - [(PYRIMIDIN-2-ILLAMIN) METHYL] PIPERIDINE-1-CARBOXYLATE FORMS
KR101357883B1 (en) Multiple interference device using time resolution
Lommen et al. Correlation between X-ray light-curve shape and radio arrival time in the Vela pulsar
Xie et al. The Doppler effect and spectral energy distribution of blazars
NIKOLENKO et al. Synchrotron radiation metrological station Cosmos at the VEPP-4 storage ring: current status and prospects
Neilsen et al. The 3 Ms Chandra campaign on Sgr A*: a census of X-ray flaring activity from the Galactic center
Qin Temporal and spectral characteristics of GRBs deduced from the curvature effect
Ding et al. Exploring the origin of multiwavelength activities of high-redshift FSRQ PKS 1502+ 106 during 2014-2018
Prokhorov VHE gamma-ray emission from radio galaxies